RCT | Baricitinib demonstrates efficacy in treatment-resistant juvenile idiopathic arthritis

Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial – The Lancet (link to abstract – $ for full-text)

Commentary on Twitter

NEW in @TheLancet—Baricitinib was efficacious with an acceptable safety profile in patients with #juvenile idiopathic #arthritis in a phase 3 withdrawal trialhttps://t.co/vZyXUwBiDZ #JIA

Plus linked Comment: https://t.co/VWofLvL427 pic.twitter.com/MGVoUz4xIv

— The Lancet Rheumatology (@TheLancetRheum) July 10, 2023